Meta-analyses show that quitting with bupropion has an odds ratio of 2.4 compared to quitting with placebo one year after the intervention [ 4].
Meta-analyses show that quitting with NRT has an odds ratio of 1.7 compared to quitting with placebo or no treatment one year after the intervention [ 4].
In addition, betel-quid chewing is more closely associated with a failure to quit smoking compared to success in quitting smoking.
Overall, after a list of related covariates are statistically controlled, the findings reveal that betel-quid chewing is more closely linked to current smokers who have never attempt to quit, compared to current smokers who have attempted to quit but have failed, smokers who are in the process of quitting, and smokers who have successfully ceased smoking.
Outcomes measure include (a) self-reported and the biochemically validated quit rate, (b) patient's smoking reduction by at least 50%% compared to baseline, (c) quit attempt(s), (d) change in the intention to quit, (e) change in risk perceptions of smoking, and (f) change in health related quality of life.
Compared to those who quit smoking <5 years, the OR of those who quitted smoking ≥20 years was 0.92 (95% CI = 0.39 2.14) in males (Table 5).
Kohler et al. reported higher meconium NIC, COT, and 3HC concentrations among women with greater duration of active smoking during pregnancy compared to women who quit smoking earlier in pregnancy, but these results were based on only eleven women who quit smoking during pregnancy [ 11].
However, compared to those who quit the survey, the remaining sample had a higher proportion of females (59% compared to 50% in 2013) and a lower proportion of single children (84% compared to 90% in 2013).
A larger proportion of smokers compared to snus users quit using tobacco during the period.
However, survivors who initiated smoking after HCT were significantly younger at HCT (mean age: 12.5 years versus 27.4 years, p<0.01), and tended to have a longer follow-up period (mean time from HCT: 15.0 years versus 12.3 years, p=0.10), and were less likely to have regular cancer/HCT-related visits (60.0% vs. 77.2%, p=0.13) when compared to survivors who quit after HCT.
